Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026
Eli Lilly is further strengthening its position in immunology with its 13th acquisition of the year, paying up to $2.875 billion for Merida Biosciences and its asset in the increasingly popular subfields ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Lilly adds to immune drug pipeline with $2.9B Merida buyout biopharmadive.com
